Betahistine 2HClCAS# 5579-84-0 |
- Amyloid β-Peptide (10-20) (human)
Catalog No.:BCC1026
CAS No.:152286-31-2
- Amyloid β-Protein (1-15)
Catalog No.:BCC1003
CAS No.:183745-81-5
- Beta-Amyloid (1-11)
Catalog No.:BCC1002
CAS No.:190436-05-6
- Myelin Basic Protein (68-82), guinea pig
Catalog No.:BCC1020
CAS No.:98474-59-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 5579-84-0 | SDF | Download SDF |
| PubChem ID | 68643 | Appearance | Powder |
| Formula | C8H14Cl2N2 | M.Wt | 209.12 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 38 mg/mL (181.71 mM) in DMSO | ||
| Chemical Name | N-methyl-2-pyridin-2-ylethanamine;dihydrochloride | ||
| SMILES | [H+].[H+].[Cl-].[Cl-].CNCCc1ccccn1 | ||
| Standard InChIKey | XVDFMHARQUBJRE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C8H12N2.2ClH/c1-9-7-5-8-4-2-3-6-10-8;;/h2-4,6,9H,5,7H2,1H3;2*1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Betahistine 2HCl Dilution Calculator
Betahistine 2HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.7819 mL | 23.9097 mL | 47.8194 mL | 95.6389 mL | 119.5486 mL |
| 5 mM | 0.9564 mL | 4.7819 mL | 9.5639 mL | 19.1278 mL | 23.9097 mL |
| 10 mM | 0.4782 mL | 2.391 mL | 4.7819 mL | 9.5639 mL | 11.9549 mL |
| 50 mM | 0.0956 mL | 0.4782 mL | 0.9564 mL | 1.9128 mL | 2.391 mL |
| 100 mM | 0.0478 mL | 0.2391 mL | 0.4782 mL | 0.9564 mL | 1.1955 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Betahistine is a histamine H3 receptors inhibitor with IC50 of 1.9 μM.
- Boc-D-Allo-Ile-OH
Catalog No.:BCC2603
CAS No.:55780-90-0
- Sanguinarine chloride
Catalog No.:BCC6481
CAS No.:5578-73-4
- Sunitinib
Catalog No.:BCC4064
CAS No.:557795-19-4
- WZ811
Catalog No.:BCC4448
CAS No.:55778-02-4
- Crocin II
Catalog No.:BCN1027
CAS No.:55750-84-0
- Litorin
Catalog No.:BCC5846
CAS No.:55749-97-8
- Oxoglaucine
Catalog No.:BCN2650
CAS No.:5574-24-3
- 3-Deoxo-1Beta-methoxyjioglutolide
Catalog No.:BCN7034
CAS No.:55732-36-0
- Stigmasta-4,22-dien-3-one
Catalog No.:BCN5745
CAS No.:55722-32-2
- Boc-D-Ile-OH
Catalog No.:BCC3407
CAS No.:55721-65-8
- Salinomycin sodium salt
Catalog No.:BCC1917
CAS No.:55721-31-8
- Secalciferol
Catalog No.:BCC1942
CAS No.:55721-11-4
- Columbianetin beta-D-glucopyranoside
Catalog No.:BCN8222
CAS No.:55836-35-6
- Halofuginone
Catalog No.:BCN8519
CAS No.:55837-20-2
- AMD-070
Catalog No.:BCC1357
CAS No.:558447-26-0
- 1-Methoxymethyl-beta-carboline
Catalog No.:BCN7911
CAS No.:55854-60-9
- VER-49009
Catalog No.:BCC5297
CAS No.:558640-51-0
- 6-beta-Hydroxyhyoscyamine
Catalog No.:BCN1915
CAS No.:55869-99-3
- Boc-D-Lys(Z)-OH
Catalog No.:BCC3423
CAS No.:55878-47-2
- 6-Hydroxysugiol
Catalog No.:BCN3154
CAS No.:55898-07-2
- Morolic acid
Catalog No.:BCN7475
CAS No.:559-68-2
- beta-Amyrin
Catalog No.:BCN5746
CAS No.:559-70-6
- Friedelin
Catalog No.:BCN5747
CAS No.:559-74-0
- Cucurbitacin R
Catalog No.:BCN7877
CAS No.:55903-92-9
Effectiveness of the combined hearing and masking devices on the severity and perception of tinnitus: a randomized, controlled, double-blind study.[Pubmed:23899886]
ORL J Otorhinolaryngol Relat Spec. 2013;75(4):211-20.
OBJECTIVE: The aim of this study was to evaluate the effect of combined hearing and tinnitus masking devices that are appropriately programmed for acoustic stimulations using wide-band noise over the specific frequency range of tinnitus. MATERIAL AND METHODS: A total of 21 patients were randomly divided into 2 groups. Group I (12 patients) was managed with betahistine dihydrochloride (2HCl) and fitted either with a combined hearing aid or a sound generator, and group II (9 patients) was treated with Betahistine 2HCl for 3 months. Audiological tests, pitch matching to determine the frequency of tinnitus, an assessment of tinnitus severity, and subjective scores (visual analog scale, VAS; Mini-Tinnitus Questionnaire) were used to assess the patients in both groups, and a loudness scale was also analyzed in group I. The results were evaluated in a double-blinded manner. RESULTS: Significant decreases in the severity of tinnitus, Mini-Tinnitus Questionnaire score and VAS were observed in both groups. No significant differences were obtained in pitch-matched frequency of tinnitus in the two groups. CONCLUSION: The findings obtained using either the combined devices or the masking devices with wide-band masking demonstrate that these devices are an effective tinnitus treatment alternative.
